Peptide library · Growth hormone axis
Tesamorelin
Egrifta
FDA approved18%less deep belly (visceral) fat vs placebo at 26 weeks in a phase 3 trial (412 patients)
What it is
A version of GHRH, the signal that tells your pituitary to release its own growth hormone.
Why researchers are interested
- FDA approved since 2010 for excess abdominal fat in HIV associated lipodystrophy.
- 37% relative drop in liver fat in a Lancet HIV trial (2019).
- Less liver fibrosis progression than placebo in that trial.
Good to know
- Prescription medicine for a specific indication; not approved for general weight loss.
- Can raise IGF-1 and blood sugar.
Evidence level: 4 of 5
Sources
FDA label (2025); Stanley et al., Lancet HIV 2019
Get the weekly research brief
New trials, FDA decisions and plain language breakdowns every Thursday. Free, plus the GLP-1 cheat sheet when you join.
Join freeRelated profiles
Educational content only. Not medical advice. Last reviewed 2026-10-17.